Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy

被引：9

作者：

Morimoto, Masahiro ^{[1
]}

Nishino, Kazumi ^{[2
]}

Wada, Kentaro ^{[1
]}

Imamura, Fumio ^{[2
]}

Konishi, Koji ^{[1
]}

Kuhara, Hanako ^{[2
]}

Tamiya, Motohiro ^{[2
]}

Inoue, Takako ^{[2
]}

Kunimasa, Kei ^{[2
]}

Kimura, Madoka ^{[2
]}

Hirata, Takero ^{[3
,4
]}

Kanayama, Naoyuki ^{[1
]}

Toratani, Masayasu ^{[1
]}

Kawachi, Hayato ^{[2
]}

Ohira, Kika ^{[2
]}

Nakanishi, Erina ^{[1
,4
]}

Ohira, Shingo ^{[1
]}

Sagawa, Tomohiro ^{[1
]}

Miyazaki, Masayoshi ^{[1
]}

Matsunaga, Takashi ^{[3
]}

Kumagai, Toru ^{[2
]}

Teshima, Teruki ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Dept Radiat Oncol, Osaka, Japan

[2] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan

[3] Osaka Int Canc Inst, Dept Med Informat, Osaka, Japan

[4] Osaka Univ, Dept Radiat Oncol, Grad Sch Med, Osaka, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 12期

关键词：

Volumetric modulated arc therapy (VMAT); intensity modulated radiation therapy (IMRT); involved field radiotherapy irradiation (IFR-IFI); twice-daily thoracic radiotherapy (BID-TRT); accelerated hyperfractionated thoracic radiotherapy (AHTRT); anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs); CONCURRENT CHEMOTHERAPY; STAGE IIIA; RADIATION; RADIOTHERAPY; SURVIVAL; COPD;

D O I：

10.21873/anticanres.14720

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The aim of this retrospective study was to detect the frequency, reasons, and significant factors for not receiving immunotherapy after chemoradiotherapy in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Thirty-four patients with NSCLC received definitive chemoradiotherapy. The endpoint of this study was receiving durvalumab within 45 days after chemoradiotherapy for NSCLC. Results: Twenty-five of 34 (73%) patients received immunotherapy within 45 days after chemoradiotherapy. The reasons for not receiving immunotherapy were radiation pneumonitis (50%), radiation esophagitis (10%), and four other reasons (40%). Univariate analysis showed that significant factors for not receiving immunotherapy were elective nodal irradiation (ENI)+ and chronic obstructive pulmonary disease (COPD)+. The rate of immunotherapy was 100% (17/17 cases) in the COPD- and ENI- group, and 16% (1/6 cases) in the COPD+ and ENI+ group. Conclusion: ENI for NSCLC complicated with COPD decreased the rate of immunotherapy after definitive chemoradiotherapy.

引用

页码：6957 / 6970

页数：14

共 50 条

[31] Feasibility of Proton Therapy For Elective Nodal Irradiation in Patients with Locally Advanced Non-small Cell Lung Cancer
Kesarwala, A. H.
Ko, C.
O'Meara, W. P.
Ning, H.
Haglund, K. E.
Xanthopoulos, E.
Rengan, R.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S251 - S251
[32] Exclusion of elective nodal irradiation does not decrease local regional control of non-small cell lung cancer
Sulman, EP
Chang, JY
Liao, Z
Guerrero, TM
Jeter, M
Stevens, C
Cox, JD
Komaki, R
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S226 - S227
[33] Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
Hamada, Akira
Soh, Junichi
Mitsudomi, Tetsuya
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 555 - 562
[34] Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study
Zhang, Kening
Zhou, Chengzhi
Gao, Jiabo
Yu, Pei
Lin, Xinqing
Xie, Xiaohong
Liu, Ming
Zhang, Jiexia
Xie, Zhanhong
Cui, Fei
Li, Shiyue
Passiglia, Francesco
Stella, Giulia Maria
Qin, Yinyin
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (11) : 2306 - 2317
[35] Influence of Chronic Obstructive Pulmonary Disease on Volatile Organic Compounds in Patients with Non-small Cell Lung Cancer
Angeles Munoz-Lucas, Maria
Jareno-Esteban, Javier
Gutierrez-Ortega, Carlos
Lopez-Guijarro, Pablo
Collado-Yurrita, Luis
Quintana-Diaz, Manuel
Callol-Sanchez, Luis
ARCHIVOS DE BRONCONEUMOLOGIA, 2020, 56 (12): : 801 - 805
[36] Prognosis of advanced stage non-small cell lung cancer: Is it different in patients with chronic obstructive pulmonary disease?
Yildirim, Fatma
Turk, Murat
Yurdakul, Ahmet Selim
Ozturk, Can
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (09): : 9603 - 9611
[37] Effects of concomitant chronic obstructive pulmonary disease on immune microenvironment in non-small cell lung cancer patients
Lin, Lin
Chen, Rui
Lin, Xiaoling
Zhuan, Sunyongxun
Li, Jianguo
Hu, Xue
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Mutational landscape of non-small cell lung cancer (NSCLC) associated with chronic obstructive pulmonary disease (COPD).
Kawaguchi, Tomoya
Koh, Yasuhiro
Ando, Masahiko
Isa, Shun-Ichi
Tamiya, Akihiro
Kubo, Akihito
Yoshimoto, Naoki
Kitagawa, Chiyoe
Saka, Hideo
Hirata, Kazuto
Matsumura, Akihide
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[39] Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer
Jeppesen, Stefan S.
Hansen, Niels-Chr. G.
Schytte, Tine
Nielsen, Morten
Hansen, Olfred
LUNG CANCER, 2016, 100 : 90 - 95
[40] Clinical characteristics and gene mutation profiles of chronic obstructive pulmonary disease in non-small cell lung cancer
Yuan, Lin
Guo, Ting
Hu, Chengping
Yang, Wei
Tang, Xiaoli
Cheng, Hao
Xiang, Yang
Qu, Xiangping
Liu, Huijun
Qin, Xiaoqun
Qin, Ling
Liu, Chi
FRONTIERS IN ONCOLOGY, 2022, 12

← 1 2 3 4 5 →